Multiple myeloma is still a fatal disease. Despite advances in high-dose chemotherapy and stem-cell transplantation and the development of novel therapeutics, relapse of the underlying disease remains the primary cause of treatment failure. Strategies for posttransplantation immunomodulation are desirable for eradication of remaining tumor cells. To this end, immunotherapy aimed at inducing myeloma-specific immunity in patients has been explored. Idiotype protein, secreted by myeloma cells, has been the primary target for immunotherapy as it is the best defined tumor-specific antigen. This chapter focuses on novel immunotherapies that are being developed to treat patients with myeloma. I will discuss potential myeloma antigens, antigen-specific T cells, and their function on myeloma tumor cells, and T-cell-based and antibody-based immunotherapies for myeloma. Furthermore, clinical studies of T-cell-based immunotherapy in the form of vaccination, allogeneic stem-cell transplantation and donor lymphocyte infusions, with or without donor vaccination using patient-derived idiotype, and future application of donor-derived or patient-derived, antigen-specific T-cell infusion in this disease are also discussed. Based on the specificity of the immune effector molecules and cells, immunotherapies with specific T cells or therapeutic antibodies may represent novel strategies for the treatment of multiple myeloma in the near future.
TUMOR ANTIGENS FOR IMMUNE TARGETING IN MM

Idiotype Proteins and Idiotype-Specific T Cells
Idiotype proteins are tumor-specific antigens, and active immunization against idiotypic determinants on malignant B cells has produced resistance to tumor growth in transplantable murine B-cell lymphoma and plasmacytoma. 24 -28 The presence of idiotype-specific T cells in the peripheral blood of patients with MM or with the benign form of the disease, monoclonal gammopathy of undetermined significance (MGUS), has been studied by detecting idiotypeinduced T-cell proliferation and cytokine secretion by using the enzyme-linked immunospot (ELISPOT) assay. 29 Idiotype-specific T cells at a low frequency were detected in 90% of patients with MM or MGUS. 30 -32 Consistent with these results, we and others have shown that T cells in patients with myeloma responded to peptides corresponding to complementaritydetermining regions I to III of heavy and light chains of the autologous M-component. 16, [33] [34] [35] We found that idiotype-induced T-cell stimulation was mainly confined to the CD4 ϩ subset in most of the patients examined and was MHC class II restricted. Idiotypespecific CD8 ϩ T cells were also demonstrated but at a lower frequency. Idiotype-specific CD4 ϩ and CD8 ϩ T cells were mainly of the type 1 subsets, as judged by their secretion of interferon (IFN)-␥ and interleukin (IL)-2. 36, 37 Moreover, the proportion of individuals who had an idiotype-specific response of the T helper-1 (T H 1)-type (IFN-␥-and/or IL-2-secreting cells) 38, 39 was significantly higher in patients with indolent disease (MGUS and MM stage I) compared with those with advanced MM (stage II/III). In contrast, cells secreting the T H 2-subtype cytokine profile (IL-4 only) 38, 39 were seen more frequently in patients with advanced MM (stage II/III). 31 A similar pattern of cytokine secretion was also reported by others. 40 Collectively, these findings indicate that the existing idiotype-specific immune response is too weak to control the growth of myeloma cells in vivo and that a shift from an idiotype-specific type 1 response, ie, T H 1 and T cytotoxic-1 (Tc1), 41 in early MM to a type 2 response (T H 2 and probably Tc2 41 ) in advanced disease may have occurred. These studies provide indirect evidence that idiotype-specific T cells may have a regulatory impact on human tumor B cells.
To examine whether idiotype-specific T cells can recognize and kill myeloma cells, we generated idiotype-specific cytotoxic T lymphocyte (CTL) lines from patients with myeloma. 42 To enhance the immunogenicity of idiotype proteins, we used dendritic cells (DCs) as antigen-presenting cells. After repeated rounds of in vitro T-cell stimulation with idiotype-pulsed autologous DCs, idiotypespecific T-cell lines, which consisted of both CD4 ϩ and CD8 ϩ T cells, were generated and propagated from the peripheral blood mononuclear cells (PBMCs) of patients with myeloma. Idiotypespecific proliferative responses were observed when these T cells were rechallenged with the autologous, but not allogeneic, idiotypepulsed DCs. By using a standard 51 chromium-release assay, our results showed that idiotype-specific CTLs not only recognized and lysed autologous idiotype-pulsed DCs but also significantly killed autologous primary myeloma cells. The cytotoxicity was MHC class I, and to a lesser extent, class II restricted, suggesting that myeloma cells could process idiotype protein and present idiotype peptides in the context of their surface MHC molecules. Taken together, these findings provide direct evidence that myeloma plasma cells express idiotype peptides-MHC molecules on their surface and are susceptible to idiotype-specific T-cell-mediated lysis.
Myeloma Plasma Cells and Myeloma-Specific T Cells
Myeloma tumor cells may contain a multitude of tumor antigens that can stimulate an increased repertoire of antitumor T cells and lead to an induction of stronger antimyeloma responses. To explore the possibility of using myeloma cells as the source of tumor antigens for immunotherapy, myeloma cell lysate-specific CTLs were generated from patients by culturing T cells with autologous DCs pulsed with freeze-thaw lysate from myeloma cells. 43 After 4 to 6 cycles of antigen stimulation, specific CTL lines containing both CD4 ϩ and CD8 ϩ T cells were obtained from 4 patients. These cell lines proliferated in response to autologous primary myeloma cells and DCs pulsed with autologous but not allogeneic, tumor lysate, and secreted predominantly IFN-␥ and tumor necrosis factor (TNF)-␣, indicating that they are type 1 T cells (T H 1 and Tc1). The CTLs had strong cytotoxic activity against autologous tumor lysatepulsed DCs and primary myeloma cells.
Myeloma-specific CTLs can also be induced and propagated by using myeloma-DC fusion cells as antigen-presenting cells. The heterokaryons generated by cancer-DC fusion cells combine the machinery needed for immune stimulation with presentation of a large repertoire of antigens. In murine plasmacytoma models, vaccination with DCs fused with mouse 4TOO plasmacytoma cells 44 or J558 myeloma cells 45 was associated with induction of antitumor humoral and CTL responses. Immunization with the fusion cells protected mice against tumor challenge and extended the survival of tumor-established mice without eradication of the tumor cells. In a more recent study, human myeloma cells, either primary myeloma cells from patients or a myeloma cell line (U266), were fused to human DCs. 46 Fusions with mature, when compared with immature, DCs induced higher levels of T-cell proliferation and activation, as assessed by intracellular IFN-␥ expression and stronger cytotoxic T-cell activity against the tumor cells. Alternatively, myelomaspecific CTLs could be generated in vitro by stimulating T cells with tumor-derived RNA-transfected autologous DCs. 47
DKK1 as a Universal Myeloma Antigen
Dickkopf-1 (DKK1) is a secreted protein that specifically inhibits the Wnt/␤-catenin signaling by interacting with the coreceptor Lrp-6. 48, 49 Previous studies have shown that the DKK1 gene has restricted expression in placenta and mesenchymal stem cells (MSCs) and not in other normal tissues. 50, 51 Recent studies demonstrated that DKK1 in patients with myeloma was associated with the presence of lytic bone lesions. 52 Immunohistochemical analysis of bone marrow biopsy specimens showed that only myeloma cells contain detectable DKK1. Recombinant human DKK1 or bone marrow serum containing an elevated level of DKK1 inhibited the differentiation of osteoblast precursor cells in vitro. Furthermore, anti-DKK1 antibody treatment was associated with reduced tumor growth in myeloma mouse models. [53] [54] [55] These results indicate that DKK1 is an important player in myeloma bone disease.
The identification of novel tumor-associated antigens, particularly those shared among patients, is urgently needed to improve the efficacy of immunotherapy for MM. For this purpose, we examined whether DKK1 could be a good candidate. We identified and synthesized DKK1 peptides for HLA-A*0201 and confirmed their immunogenicity by in vivo immunization of HLA-A*0201 transgenic mice. We detected low frequencies of DKK1 peptidespecific CD8 ϩ T cells in patients with myeloma by using peptide tetramers and generated peptide-specific T-cell lines and clones from HLA-A*0201 ϩ blood donors and patients with myeloma. These T cells efficiently lysed peptide-pulsed but not unpulsed T2 or autologous DCs, DKK1 ϩ /HLA-A*0201 ϩ myeloma cell lines U266 and IM-9 and, more importantly, HLA-A*0201 ϩ primary myeloma cells from patients. No killing was observed on DKK1 ϩ /HLA-A*0201myeloma cell lines and primary myeloma cells or HLA-A*0201 ϩ normal lymphocytes, including B cells ( Fig. 1 ). These T cells were also therapeutic in vivo against established myeloma in SCID-hu mice after adoptive transfer. These results indicate that these T cells were potent CTLs and recognized DKK1 peptides naturally presented by myeloma cells in the context of HLA-A*0201 molecules. Hence, our study identified DKK1 as a potentially important antigen for immunotherapy in MM.
Other Antigens
Recent studies have shown that the cancer-testis antigens MAGE-3 and NY-ESO-1 may be expressed by myeloma cells. 56 -58 DNA microarray analysis of gene expression of Ͼ95% pure myeloma cells from more than 300 patients showed that the genes of these antigens were expressed in the tumor cells, particularly from patients with relapsed disease or abnormal cytogenetics (in 7%-20% of MGUS and newly diagnosed MM and in 40% to 50% of relapsed patients or in patients with cytogenetic abnormalities). 59, 60 With the use of specific monoclonal antibodies (mAbs) against MAGE-3 or NY-ESO-1, it was evident that the proteins of these antigens were also expressed in the tumor cells of patients with positive gene expression. We then generated MAGE-3-and NY-ESO-1-specific CTLs from healthy individuals by using HLA-A1-restricted or HLA-A2-restricted MAGE-3-derived and NY-ESO-1-derived synthetic peptides as the antigens with which to pulse autologous No killing was observed with K562 cells, unpulsed target cells, or myeloma cell lines that were HLA-A1 positive but MAGE-3 negative. 61 Similar results were obtained with NY-ESO-1-specific CTLs. 62 Furthermore, other antigens, such as MUC-1, 63-65 sperm protein 17 (Sp17), 66, 67 and HM1.24, 68 -70 may also be expressed on myeloma cells, and MHC-restricted antigen (MUC-1 71 and Sp17 72 )specific CTLs have been generated from patients with myeloma that were able to lyse myeloma cells. Recently, a phase I/II clinical trial has been initiated to examine the safety and efficacy of Sp17-pulsed DC vaccination in patients with myeloma. 67 However, there is evidence that Sp17 is also expressed on normal T and B cells 73 ; hence, although these antigens may be potential targets, further research is warranted to examine their applicability for immunotherapy in MM.
T CELL-BASED IMMUNOTHERAPY IN MM
Idiotype-Based Protein Vaccines for Myeloma
Our group at the Karolinska Institute, Stockholm, Sweden, was the first to introduce active immunization of patients with myeloma with Id proteins. 74, 75 Considering that immunotherapy may work better in immunocompetent patients with a low tumor burden, we targeted untreated patients with early disease. In our first pilot study, we recruited and immunized 5 previously untreated patients with stages I to III MM with the autologous Id protein precipitated in an aluminum phosphate suspension. 74 In 3 patients, an anti-Id T-cell response, detected by enumeration of IFN-␥-and IL-2-secreting cells by ELISPOT assay, was amplified 1.9-to 5-fold during the immunization. The number of B cells secreting anti-Id antibodies also increased in these 3 patients, and 2 of the 3 patients had a gradual decrease of blood CD19 ϩ B cells. However, the induced T-cell response was transient and was eliminated during repeated immunization. The disease was stable in all patients, and no side effects or clinical response were noted. In our second series of the study, immunization was performed by subcutaneous or intradermal injection of Id protein and granulocyte-monocyte colonystimulating factor (GM-CSF). 75 Five patients with IgG myeloma were treated and an Id-specific type 1 T-cell response developed in all of them. The response involved both CD8 ϩ and CD4 ϩ subsets and was mainly MHC class I restricted. There was a transient rise in B cells producing IgM antiidiotypic antibodies in all patients. One patient had a clinical response, defined by a significant decrease in serum Id protein (from 20 to 7 g/L) and normalization of serum Ig levels, which lasted for Ͼ1 year after immunization was started. Although these studies involved a limited number of patients, the results clearly indicated that Id protein vaccination, particularly in combination with GM-CSF, was able to induce specific anti-Id cellular and humoral immune responses, which were occasionally accompanied by a clinical response in treated patients. Furthermore, idiotype vaccination combined with IL-12 also was efficient at inducing myeloma-specific immune responses in patients with myeloma. 76 Other clinical settings for immunotherapy could be minimal residual disease status achieved by high-dose chemotherapy and early host immunologic recovery after stem-cell transplantation. These are supported by a study from Massaia et al 77 showing that Id vaccination of patients with myeloma with minimal residual disease was able to induce a strong Id-specific cellular immunity in many of the patients. In their study, 12 patients who had been treated with high-dose chemotherapy followed by stem cell support received Id-keyhole limpet hemocyanin (KLH) vaccines and a low dose of GM-CSF or IL-2. In most of the patients, the interval between the completion of prior high-dose therapy and vaccination was only 2 to 3 months. Generation of Id-specific T-cell proliferative responses was documented in only 2 cases; however, a positive, Id-specific, delayed-type hypersensitivity (DTH) skin test reaction was observed in 8 of the 10 patients studied. The induction of humoral and cellular immune responses to KLH was observed in 100% and 80% of the patients, respectively, suggesting that the majority of patients were already able to mount immune responses to KLH shortly after high-dose therapy and stem-cell transplantation. Collectively, these results indicate that immunization of patients with myeloma with the autologous Id protein, together with GM-CSF, might be a promising method of immunotherapy. 78
DC-Based Vaccines for Myeloma
Preclinical studies have shown that DCs generated from patients with myeloma were functional and could efficiently present Id determinants to autologous T cells. 79, 80 Compared with their progenitor monocytes, Id-pulsed DCs induced not only a stronger Id-specific T-cell response but also a predominant type 1 (IFN-␥) T-cell response. 79 Both type 1 and type 2 (IFN-␥ and IL-4) T-cell responses were noted when monocytes were used as the APCs. These results indicate that DCs pulsed with Id protein can be used to induce the type 1 anti-Id response in patients with myeloma.
Wen et al 81 reported vaccinating a patient with MM with autologous Id protein-pulsed DCs generated from blood adherent cells. Enhanced Id-specific cellular and humoral responses were observed in the patient. The immune responses were associated with a transient minor decrease in the serum Id protein level. In their subsequent study, 6 additional patients were treated according to the same protocol. 82 
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The Cancer Journal • Volume 15, Number 6, November/December 2009 with Id-pulsed DC vaccination in 12 patients with myeloma after autologous peripheral blood stem-cell transplantation. Their results were less compelling because only 2 of 12 patients mounted cellular Id-specific proliferative responses as the sole evidence for effective vaccination. Nevertheless, all patients with myeloma could mount a strong anti-KLH response despite recent high-dose therapy. Similar results were also obtained in their subsequent study involving 26 patients treated on the same protocol. 84 Although 24 of 26 patients generated a KLH-specific cellular proliferative immune response, an Id-specific proliferative immune response developed in only 4 patients. No clinical benefit was observed. These results suggest that DC-based Id vaccination is feasible after transplantation and can induce an Id-specific T-cell response in certain patients.
Other clinical trials of Id-pulsed DC vaccination in patients with myeloma have been reported. Cull et al 85 reported on their experience of vaccinating 2 patients with advanced refractory MM with Id-pulsed DCs combined with GM-CSF. An anti-Id T-cell proliferative response was detected in both patients, which was associated with IFN-␥ production by the T cells. One patient also had an anti-Id humoral response. Titzer et al 86 treated 11 patients with advanced MM with Id-pulsed, CD34 ϩ stem cell-derived DCs and GM-CSF. After vaccination, 3 of 10 analyzed patients showed an increased anti-Id antibody titer, and 4 of the 10 patients had an Id-specific T-cell response measured by ELISPOT assay.
To improve the efficacy of DC vaccination in myeloma, we investigated the use of Id-pulsed mature DCs administered subcutaneously. In our study, 5 patients with stable partial remission after high-dose chemotherapy were vaccinated at least 4 months posttransplantation. 87 After 4 DC vaccinations, Id-specific T-cell responses, detected by ELISPOT assays (4 patients) and proliferation assays (2 patients), were elicited in 4 patients and anti-Id B-cell responses in all 5 patients. The cytokine-secretion profile of activated T cells demonstrated a type 1 T-cell response. A 50% reduction in serum Id protein was observed in 1 immunologically responding patient and persisted for more than 1 year; stable disease was noted in the other 3 patients. The remaining patient without an immune response to the vaccination experienced disease relapse. Similar results were recently reported by Curti et al. 88 In their study, 15 patients received DCs pulsed with Id proteins or their peptides, and an Id-specific IFN-␥ response was seen in 8 patients. Clinically, 7 of the 15 patients had stable disease after a median follow-up of 26 months, 1 patient achieved durable partial remission after 40 months and 7 patients progressed. Alternatively, Id-pulsed allogeneic DCs could also be used to vaccinate patients with myeloma. 89 Taken together, these results indicate that subcutaneous DC vaccination indeed induces better antimyeloma responses than intravenous DC vaccination.
DC vaccines can also be made in the form of fusion of tumor cells with DCs. The heterokaryons generated by tumor-DC fusion cells combine the machinery needed for immune stimulation with presentation of a large repertoire of antigens. Vaccination with fusions of tumor cells and DCs is an effective treatment in animal tumor models 90, 91 and possibly in patients with metastatic renal carcinoma. 92 In a murine plasmacytoma model, vaccination with DCs fused with mouse 4TOO plasmacytoma cells was associated with induction of antitumor humoral and CTL responses. 44 Immunization with the fusion cells protected mice against tumor challenge and extended the survival of tumor-established mice without eradication of the tumor cells. Addition of IL-12 helped eradicate the established tumor. In a more recent study, human myeloma cells, either primary myeloma cells from patients or a myeloma cell line, U266, were fused to human DCs. 93 Fusions with mature rather than immature DCs induced higher levels of T-cell proliferation and activation, as assessed by intracellular IFN-␥ expression, and stron-ger CTL activity against the tumor cells. Similar results were also obtained by other investigators. 94, 95 Based on these results, a clinical trial was designed to evaluate the efficacy of vaccinating patients with myeloma with a fusion of myeloma cells and autologous mature DCs. 93 
DNA Vaccines for Myeloma
Various approaches to antitumor therapy that use both antigen-encoding DNA and noncoding nucleotides as components of genetic vaccination are currently being explored. 96 These strategies include the construct that fuses an scFv incorporating both variableregion genes necessary to encode the Id determinants with fragment C of tetanus toxin 28 and gene transfer of cytokines or costimulatory molecules into myeloma cells by nonviral and viral vectors. 97 In animal studies, DNA vaccination promoted specific immune responses and induced strong protection against B-cell lymphoma and myeloma. 28, 98 These strategies may have implications for immunotherapy in human diseases.
A phase I study has been completed to evaluate the feasibility and safety of vaccinating patients with MM after high-dose chemotherapy with adenovector-engineered, IL-2-expressing autologous plasma cells. 99 Eight patients were enrolled, and vaccines were successfully made in 6 patients, who received 1 to 5 subcutaneous injections of 3.5 to 9.0 ϫ 10 7 cells/injection. Vaccines were well tolerated, with only minor systemic symptoms reported. Vaccination induced a local inflammatory response consisting predominantly of CD8 ϩ T cells. However, no specific antitumor immune or clinical responses were noted. Hence, further studies of immunologic and clinical efficacy are needed to examine the applicability of this approach to the treatment of patients.
Combined Donor Vaccination and Allogeneic Stem-Cell Transplantation
Allogeneic stem-cell transplantation showed efficacy in MM but was accompanied by severe GVHD. 100 -103 One strategy for enhancing antimyeloma effects without aggravating GVHD is to target an immune response selectively against a defined tumorspecific antigen. This could be accomplished by eliciting an antimyeloma immune response in allogeneic HSCT donors by active immunization before allogeneic HSCT and/or DLI. This strategy was pioneered by Kwak et al. 104 An HLA-matched donor received 2 subcutaneous immunizations of patient-derived idiotype conjugated to KLH at a 1-week interval before marrow harvest. The recipient patient demonstrated no preexisting antiidiotype immunity pretransplantation. Thirty and 60 days after conditioning with busulfan and cyclophosphamide and transfer of unmanipulated donor bone marrow, significant lymphocyte proliferative responses against the idiotype were detected in the recipient. A CD4 ϩ , idiotypespecific T-cell line was generated from the recipient's blood, which was, unequivocally, of donor origin because in situ hybridization assay demonstrated the presence of Y chromosome in more than 95% of the T cells. By day 220, a greater than 90% reduction in serum M-protein was observed, which persisted for over 3 years.
On the basis of this encouraging result from the single patient mentioned above, the investigators, then at the National Cancer Institute, opened a clinical trial of donor immunization in MM under the Food and Drug Administration-approved Investigational New Drug application in collaboration with the Arkansas myeloma research group at the University of Arkansas. The clinical protocol was designed to explore whether a booster immunization of the recipient might improve the potency and duration of the transferred idiotype-specific response. Five additional donor-recipient pairs were enrolled and vaccinated with idiotype-KLH protein plus GM-CSF. Two recipients succumbed to early postallogeneic stem-cell transplantation complications, unrelated to vaccination. The 3 re-
The Cancer Journal • Volume 15, Number 6, November/December 2009 Novel Immunotherapies maining recipients achieved and remained in continuous complete remission 3.5, 4, and 5 years after transplantation. One recipient suffered from chronic GVHD and was on chronic steroid therapy, whereas the other 2 recipients and all the donors were medically well, without any significant complications. In all 3 recipients, transfer of T-cell responses to the KLH carrier protein has been documented. Analysis and serial monitoring of idiotype-specific T-cell responses in the donors and recipients have been in progress. 105 Taken together, these proof-of-principle studies demonstrate a direct transfer of myeloma idiotype-specific T-cell immunity from donor to recipient after allogeneic stem-cell transplantation or donor lymphocyte infusion. These results also suggest that the donorderived T-cell response was not blocked by circulating myeloma idiotype protein in recipient during and after transplantation or inhibited by the immunosuppressive medication used for GVHD prophylaxis in the patients. Furthermore, GVHD did not seem to be exacerbated secondary to this immunotherapeutic maneuver.
Immunotherapy With Donor-Derived or Patient-Derived, Tumor-Specific Lymphocytes
Successful immunotherapy of patients with tumors requires the in vivo generation of large numbers of highly reactive antitumor lymphocytes that are not restrained by normal tolerance mechanisms and are capable of sustaining immunity against tumor cells. Immunizing patients with MM with myeloma antigens such as the idiotype proteins or tumor lysate can increase the number of circulating antigen-specific T cells. To date, this has not correlated with clinical tumor regression, suggesting that the numbers of these T cells, particularly those of the CTLs, are still insufficient to cause major tumor damage, and/or there are defects in function or activation of these T cells.
Falkenburg et al 106 reported the first successful treatment of a hematological malignancy with donor-derived tumor-specific CTL lines. A patient with accelerated phase chronic myeloid leukemia (CML) received infusions of 3 donor-derived leukemia-reactive CTL lines at 5-week intervals at a cumulative dose of 3.2 ϫ 10 9 CTLs after allogeneic HSCT. The CTLs were selected based on their ability to inhibit the in vitro growth of CML progenitor cells and to lyse the leukemic cells from the patient. Shortly after the third infusion, complete eradication of the leukemic cells was observed, as shown by cytogenetic analysis, fluorescence in situ hybridization, molecular analysis of BCR/ABL mRNA, and chimerism studies. Thus, these results show that in vitro cultured leukemia-reactive CTLs can be successfully applied to treat accelerated phase CML after allogeneic HSCT.
In addition to obtaining tumor-specific CTLs from donors, these cells can also be obtained from patients themselves, ex vivo expanded, and used adoptively to eradicate tumor cells. In patients with metastatic melanoma refractory to treatment with high-dose IL-2 and to chemotherapy, the transfer of in vitro-activated and expanded autologous antitumor lymphocytes plus IL-2 into lymphodepleted patients mediated objective cancer regression in 6 of 13 patients. Persistence of the transferred cells was seen for up to 4 months after cell administration. 107 The number of patients enrolled on this protocol was expanded, and the investigators have observed objective cancer regression in 18 of 35 patients (51%), many of whom have bulky disease. 108 These studies demonstrate that adoptive transfer of tumor-reactive lymphocytes after nonmyeloablative conditioning can be an effective treatment for patients with metastatic cancers.
ANTIBODY-BASED IMMUNOTHERAPY IN MM
Within the past decade, mAbs have broadened the therapeutic armamentarium in oncology. 109 Hematological malignancies are recognized as particularly promising targets, reflected by the current list of Food and Drug Administration-approved mAbs that are used to treat patients. 110, 111 The mAbs exert their in vivo effect largely through the immunologic effector mechanisms of complementmediated lysis (CDC) and/or antibody-dependent cell-mediated cytotoxicity (ADCC). Thus, their efficacy depends on intact immunologic mechanisms in the treated patients. Although the molecules targeted by these mAbs are usually widely expressed on normal lymphoid and myeloid cells in addition to malignant cells, the therapeutic efficacy of these mAbs has been promising. 109 -111 Nevertheless, it will be useful to develop mAbs with an inherent capability to kill tumor cells, ie, independent of complement and ADCC, and with selectivity toward neoplastic cells.
Targeting Surface ␤ 2 -Microglobulin to Induce Apoptosis in Myeloma Cells
␤ 2 -microglobulin (␤ 2 M) is an 11.6-kDa nonglycosylated polypeptide composed of 100 amino acids. It is part of the MHC class I molecule on the cell surface of nucleated cells. Its best characterized function is to interact with and stabilize the tertiary structure of the MHC class I ␣-chain. 112 Because it is noncovalently associated with the ␣-chain and has no direct attachment to the cell membrane, ␤ 2 M on the cell surface can exchange with free ␤ 2 M present in serum-containing medium. 113 Free ␤ 2 M is found in body fluids under physiological conditions as a result of intracellular release. Elevated levels of serum ␤ 2 M are present in hematological malignancies, including lymphomas, 114 leukemias, 115, 116 and MM 2,117 and correlate with a poor prognosis regardless of a patient's renal function. 117, 118 This observation suggests an important, yet unidentified, role of this protein in these malignancies. Although examining the effects of ␤ 2 M on myeloma cells, we made a novel and exciting discovery, namely that mAbs against ␤ 2 M have a remarkably strong apoptotic effect on myeloma cells and on other hematological tumor cells. 119 Anti-␤ 2 M mAbs induced apoptosis in up to 90% of cells in a 48-hour culture in all tested human myeloma cell lines (n ϭ 8) and primary myeloma cells from patients (n ϭ 10). The mAbs also kill ␤ 2 M/MHC class I-bearing lymphoma and leukemia cells. Anti-MHC class I mAbs (LY5.1, IgG1 or W6/32, and IgG2a), purified mouse IgG and IgG1 had no effect. Cell death occurred rapidly, without the need for exogenous immunologic effector mechanisms (eg, complement or NK cells) or secondary crosslinking. Anti-␤ 2 M mAb-induced apoptosis in myeloma cells were not blocked by soluble ␤ 2 M (10 -100 g/mL, 3-to 30-fold higher than the levels in most patients with MM), IL-6, or other myeloma growth and survival factors and was stronger than apoptosis observed with chemotherapy drugs currently used to treat MM (eg, dexamethasone).
Although the expression of ␤ 2 M on normal hematopoietic cells is a potential safety concern, the mAbs were selective to tumor-transformed cells and did not induce apoptosis of normal cells, including T and B lymphocytes, plasma cells, and purified CD34 ϩ stem cells. Furthermore, the mAbs selectively and effectively killed myeloma cells without damaging osteoclasts (OCs) or PBMCs in their cocultures with myeloma cells. More importantly, anti-␤ 2 M mAbs are therapeutic in vivo in xenograft SCID (Fig. 2) and SCID-hu mouse models, 119 and in the HLA-A2-transgenic NOD-SCID (A2-NOD-SCID) models of myeloma, in which every mouse tissue expresses human MHC class I/␤ 2 M molecules and circulating human ␤ 2 M could reach the levels seen in most patients with myeloma without causing damage to normal human hematopoiesis or murine organs. 120 Interestingly, after our publication,
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The Cancer Journal • Volume 15, Number 6, November/December 2009 others have reported similar results using anti-MHC class singlechain Fv diabody or anti-␤ 2 M antibodies, respectively, in human myeloma, 121 renal cell carcinoma, 122 and prostate cancer. 123 Therefore, such mAbs offer the potential for a therapeutic approach to hematological malignancies. The mAbs induced apoptosis in myeloma cells by recruiting MHC class I to lipid rafts, activated JNK, and inhibited PI3K/Akt and ERK pathways. 119 Growth and survival cytokines such as IL-6 and IGF-I, which could protect myeloma cells from dexamethasoneinduced apoptosis, did not affect mAb-mediated cell death. We elucidated the mechanisms underlying anti-␤ 2 M mAb-induced PI3K/Akt and ERK inhibition and the inability of IL-6 and IGF-I to protect myeloma cells from mAb-induced apoptosis. We focused on lipid rafts and confirmed that these membrane microdomains are required for IL-6 and IGF-I signaling. By recruiting MHC class I into lipid rafts, anti-␤ 2 M mAbs excluded IL-6 and IGF-I receptors and their substrates from the rafts. The mAbs were not only redistributed the receptors in cell membrane but also abrogated IL-6or IGF-I-mediated JAK/STAT3, PI3K/Akt, and Ras/Raf/ERK pathway signaling, which are otherwise constitutively activated in myeloma cells. 124 Thus, our study further defines the tumoricidal mechanism of the mAbs and provides strong evidence to support the potential of these mAbs as therapeutic agents for myeloma.
Anti-CS1 Antibodies
CS1, a glycoprotein and a member of the Ig gene superfamily, has been found to be highly expressed on tumor cells from patients with myeloma, and soluble serum CS1 correlates with active disease in patients with myeloma. 125 However, CS1 is also expressed by NK cells, NKT cells, and CD8 ϩ T cells. 125 Recent studies demonstrated that CS1 promotes myeloma cell adhesion, clonogenic growth, and tumorigenicity through c-maf-mediated interactions with bone marrow stromal cells. 126 As the above data suggest that CS1 could be a novel target for therapy, a humanized mAb against CS1, HuLuc63, was generated. 125 HuLuc63 inhibited myeloma cell binding to bone marrow stromal cells and induced ADCC against myeloma cells in dose-dependent and CS1-specific manners. Furthermore, the mAb mediated autologous ADCC against primary myeloma cells resistant to conventional or novel therapies and pretreatment with conventional or novel antimyeloma drugs markedly enhanced HuLuc63-induced myeloma cell lysis. In vivo injection of the mAb significantly induced tumor regression in xenograft myeloma mouse models. 127 Based on these results, phase I clinical trials are underway to evaluate the safety and toxicity of the mAb in patients with myeloma.
Other Antibodies
Inhibiting DKK1 activity by using specific mAbs to treat MM and myeloma-associated bone disease is a novel approach because DKK1 has been shown to contribute to osteolytic bone disease in MM by inhibiting the differentiation of osteoblasts. 52 A humanized DKK1-neutralizing mAb, BHQ880 has been developed by Novartis and tested in preclinical studies. [53] [54] [55] In both murine 54 and xenograft human 53,55 myeloma mouse models, this mAb was shown to sustain or increase the numbers of osteoblasts, protect myeloma-induced bone loss, and reduce the development of osteolytic bone lesions. Furthermore, the mAb was also shown to inhibit the growth of xenografted human myeloma cells in SCID-hu 55 or SCID-rab 53 mouse models. These results provide the rationale for clinical evaluation of BHQ880 to improve bone disease and to inhibit myeloma growth.
Another potential target is CD40, which is expressed on B-cell tumors including MM. Two humanized anti-CD40 mAbs, SGN-40 and HCD122, have been developed and tested in preclinical studies. 128, 129 These mAb induced modest cytotoxicity in myeloma cell lines and primary myeloma cells from patients but can effectively kill myeloma cell through mediating ADCC. Furthermore, the immunomodulatory drug lenalidomide further augmented anti-CD40 mAb-induced cytotoxicity in human myeloma cells. 130 In addition to anti-CD40 mAbs, other mAbs currently in clinical trials include anti-CD74, anti-CD56, and anti-HM1.24. 131
CONCLUSIONS
Various clinical immunotherapy treatment strategies have been tested in B-cell malignancies, including MM. Most of these have focused on targeting idiotype-specific immunity. Idiotypebased vaccines have been shown to induce or enhance idiotypespecific immunity, indicating that the vaccines are able to elicit a specific immune response. However, clinical response is still a rare event, occurring only in a minority of treated patients, suggesting that the elicited or enhanced immunity is still too weak to cause significant tumor destruction. Alternatively, a nonbeneficial immune response (such as the type 2 T-cell response) may also be generated by immunization, which may enhance tumor B-cell growth and facilitate differentiation into plasma cell tumors.
Ideally, a tumor-specific immunotherapy should induce or expand only the beneficial immune responses mediated by CTLs (T H 1 and Tc1 subsets) that have sufficient cytotoxic effects toward tumor cells but not normal cells. Further studies are warranted so that we can better understand the immune regulation mechanism in MM.
